Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASLAN PHARMACEUTICALS LIMITED SPON ADS EACH REP 25 ORD SHS (P/S)

0.6000
+0.0000
Volume:- -
Turnover:- -
Market Cap:1.70M
PE:-0.04
High:0.6000
Open:0.6000
Low:0.6000
Close:0.6000
Loading ...

Company Profile

Company Name:
ASLAN PHARMACEUTICALS LIMITED SPON ADS EACH REP 25 ORD SHS (P/S)
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.